TRIM24 Antibody
| Code | Size | Price |
|---|
| PSI-7383-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7383-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
TRIM24 Antibody: PTC6, TF1A, TIF1, RNF82, TIF1A, hTIF1, TIF1ALPHA, Transcription intermediary factor 1-alpha, E3 ubiquitin-protein ligase TRIM24, TIF1-alpha
Application Note:
TRIM24 antibody can be used for detection of TRIM24 by Western blot at 0.5 - 1 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
TRIM24 Antibody: TRIM24 (TIF1), a member of the tripartite motif (TRIM) family, plays a role in the regulation of cell proliferation and apoptosis. TRIM24 localizes to nuclear bodies and is thought to associate with chromatin and heterochromatin-associated factors. The TRIM motif includes three zinc-binding domains (RING, B-box type 1 and B-box type 2) and a coiled-coil region. TIF1 mediates transcriptional events by interactions with the AF2 region of several nuclear receptors, such as the estrogen, retinoic acid and vitamin D3 receptors. Defects in TRIM24 are a cause of thyroid papillary carcinoma (TPC).
Background References:
- Fraser RA, Heard DJ, Adam S, et al. The putative cofactor TIF1 is a protein kinase that is hyperphosphorylated upon interaction with liganded nuclear receptors. J. Biol. Chem. 1998; 273:16199-204.
- Tisserand J, Khetchoumian K, Thibault C, et al. Tripartite motif 24 (Trim24/Tif1a) tumor suppressor protein is a novel negative regulator of interferon (IFN)/signal transducers and activators of transcription (STAT) signaling pathway acting through retinoic acid receptor a (Rara) inhibition. J. Biol. Chem. 2011; 286:33369-79.
- Herquel B, Ouararhni K, Khetchoumian K, et al. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 2011; 108:8212-7.
- Klugbauer S and Rabes HM. The transcription co-activator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 1999;18:4388-93.
Buffer:
TRIM24 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
TRIM24 antibody was raised against a 19 amino acid peptide near the center of human TRIM24.
The immunogen is located within amino acids 530 - 580 of TRIM24.
The immunogen is located within amino acids 530 - 580 of TRIM24.
NCBI Gene ID #:
8805
NCBI Official Name:
tripartite motif containing 24
NCBI Official Symbol:
TRIM24
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 112, 116
Observed: 108, 1 of 2 isoforms
Observed: 108, 1 of 2 isoforms
Protein Accession #:
NP_056989
Protein GI Number:
47419911
Purification:
TRIM24 Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
SPECIFICITY:
At least two isoforms of TRIM24 are known to exist.
Swissprot #:
O15164
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | TRIM24 Peptide | PSI-7383P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|